Biggest News Aggregation in the World
📰 Years Study News

Years Study News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Years Study. Real-time updates on events, politics, business and more.

European Medicines Agency Approves Pfizer's 20-Valent Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease and Pneumonia in Adults

Pfizer Inc. (NYSE:PFE) today announced that the European Medicines Agency (EMA) has approved the company’s 20-valent pneumococcal conjugate vaccine (PCV20), which will be marketed in the European Union (EU) under the brand name APEXXNAR. The vaccine is approved for active immunization for the prevention of invasive ...
United States Nanette Cocero Drug Administration Exchange Commission Pfizer Inc European Union

Pfizer Inc.: European Medicines Agency Approves Pfizer's 20-Valent Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease and Pneumonia in Adults

APEXXNAR [pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed)] is the first pneumococcal conjugate vaccine to help protect adults ages 18 years and older against 20 serotypes responsible
United States Nanette Cocero Drug Administration Exchange Commission Pfizer Inc European Union

Advisory Committee on Immunization Practices Votes to Recommend Routine Use of Pfizer's PREVNAR 20 in Adults

One dose of PREVNAR 20 is recommended by ACIP for adults ages 65 and older and adults ages 19 to 64 with certain risk conditions New PREVNAR 20 one-dose guidance helps simplify long-standing adult pneumococcal recommendations Pfizer Inc. announced today that the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to recommend PREVNAR 20 ™ for routine use to help ...
New York United States Luis Jodar Nanette Cocero Centers For Disease Us Department Of Health

U.S. FDA Approves PREVNAR 20, Pfizer's Pneumococcal 20-valent Conjugate Vaccine for Adults Ages 18 Years or Older

First approval of a conjugate vaccine that helps protect against 20 serotypes responsible for the majority of invasive pneumococcal disease and pneumonia, 1,2,3,4,5,6,7 including seven responsible for 40% of pneumococcal disease cases and deaths in the U.S. Helps protect against more serotypes of pneumococcal disease than any other conjugate vaccine Builds on Pfizer’s more than 20-year legacy and innovation in ...
United States New York Nanette Cocero Bryan Dunn Kathrinu Jansen Steve Danehy

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science